Tests MRTX1719 in advanced solid tumors with a specific MTAP gene deletion
Tests MRTX1719 in adults with advanced solid tumors carrying an MTAP gene deletion.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Brookline, Chapel Hill, Chicago, Dallas, Fairfax, Fort Worth, Grand Rapids, Houston, Jacksonville, Lone Tree, Milwaukee, Mineola, Nashville, New Brunswick, New York, Norton Shores, Orlando, Phoenix, Port Jefferson Station, Rochester, San Antonio, Seattle, and Tyler, United StatesSee the 24 sites
- Trial code
- Registry title
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 336 people, planned
- Started
- 9 Jun 2022
- Expected to end
- 10 Dec 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- MRTX1719
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an advanced solid tumor that cannot be removed by surgery or has spread, and whose tumor has a homozygous deletion of the MTAP gene.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Solid tumor that cannot be removed by surgery or has spread (unresectable or metastatic), confirmed under the microscope.
- Earlier treatment
- People who had earlier treatment with a PRMT5 or MAT2A inhibitor cannot join.
- Biomarker or test result
- Homozygous deletion of the MTAP gene found in tumor tissue.
Main reasons for not taking part
- Earlier treatment with a PRMT5 or MAT2A inhibitor
- Active brain metastases or carcinomatous meningitis
- Significant coughing up of blood or bleeding within 4 weeks before the first dose
- Major surgery within 4 weeks before the first dose
- Bowel or stomach conditions that could change how the medicine is absorbed or make swallowing pills impossible
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue
- Unresectable or metastatic disease
- Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
Who cannot take part
- Prior treatment with a PRMT5 or MAT2A inhibitor therapy
- Major surgery within 4 weeks of first dose of study treatment
- History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment
- History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications
- Cardiac abnormalities
- Active brain metastases or carcinomatous meningitis
- Other protocol-defined Inclusion/Exclusion criteria apply
Where in United States
- Dana-Farber Cancer InstituteBrookline, United StatesContact: Pasi Janne, Site 103Taking people
- University of North CarolinaChapel Hill, United StatesContact: Shetal Patel, Site 125Taking people
- University of North Carolina - Gastroenterology and HepatologyChapel Hill, United StatesContact: Shetal Patel, Site 107Taking people
- Chicago, IllinoisHospital not named in the registryNo longer taking part
- UT SouthwesternDallas, United StatesContact: Salwan Al Mutar, Site 120Taking people
- Virginia Cancer Specialists PCFairfax, United StatesContact: Alexander Spira, Site 122Taking people
- Texas Oncology - DFWFort Worth, United StatesContact: Andrew Paulson, Site 111Taking people
- The Cancer & Hematology CentersGrand Rapids, United StatesContact: Sreenivasa Chandana, Site 106Taking people
- MDACCHouston, United StatesContact: Jordi Ahnert, Site 105Taking people
- Mayo ClinicJacksonville, United StatesContact: Hani Babiker, Site 114Taking people
- Rocky Mountain Cancer Centers, LLP - OncologyLone Tree, United StatesContact: Robert Jotte, Site 109Taking people
- Milwaukee, WisconsinHospital not named in the registryNo longer taking part
- Perlmutter Cancer Center at NYU Langone Hospital - Long IslandMineola, United StatesContact: Kristen Spencer, Site 129Taking people
- Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: Elizabeth Davis, Site 132Taking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesContact: Kristen Spencer, Site 127Taking people
- David H Koch, Memorial Sloan Kettering Cancer CenterNew York, United StatesContact: Kathryn Arbour, Site 104Taking people
- Cancer and Hematology Centers of Western MichiganNorton Shores, United StatesContact: Sreenivasa Chandana, Site 131Taking people
- Sarah Cannon Research Institute at Florida Cancer SpecialistsOrlando, United StatesContact: Cesar Perez Batista, Site 121Taking people
- Mayo ClinicPhoenix, United StatesContact: Tanios Bekaii-Saab, Site 113Taking people
- New york cancer and blood specialists - OncologyPort Jefferson Station, United StatesContact: Richard Zuniga, Site 101Taking people
- Mayo ClinicRochester, United StatesContact: Lei Deng, Site 112Taking people
- South Texas Accelerated Research TherapeuticsSan Antonio, United StatesContact: Kyriakos Papadopoulos, Site 102Taking people
- Seattle, WashingtonHospital not named in the registryNo longer taking part
- Texas Oncology, P.A. - OncologyTyler, United StatesContact: Donald Richards, Site 110Taking people
About the trial
What the trial wants to find out
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
The 3 groups in the trial
- Phase 1/1BTreatment being tested
Dose Escalation/Evaluation
Treatment: MRTX1719
- Phase 1b Sub-studies 1-4Treatment being tested
Treatment: MRTX1719
- Phase 1b Sub-study 5Treatment being tested
Treatment: MRTX1719
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Plain-language title
- Tests MRTX1719 in advanced solid tumors with a specific MTAP gene deletionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 September 2026